1. ESMO 2014: new trends in precision medicine

   • J. F. Morere
   • P. Innominato

   Editorial 13 December 2014 Pages: 293 - 294

2. Curcumin and lung cancer—a review

   • Hiren J. Mehta
   • Vipul Patel
   • Ruxana T. Sadikot

   Review 21 May 2014 Pages: 295 - 310

   

3. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort

   • Annie Fourrier-Réglat
   • Denis Smith
   • on behalf of the ETNA study group.

   Original Research 05 December 2013 Pages: 311 - 319

   

4. Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a Phase II study

   • Carmen Balaña
   • Miguel J. Gil
   • Eugenia Verger

   Original Research 15 January 2014 Pages: 321 - 329

   

5. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion

   • S. F. Mulder
   • M. J. Boers-Sonderen
   • C. M. L. van Herpen

   Original Research 21 January 2014 Pages: 331 - 338

   

6. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT

   • Marye J. Boers-Sonderen
   • Lioe-Fee de Geus-Oei
   • Carla M. L. van Herpen

   Original Research 01 March 2014 Pages: 339 - 347

   

7. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients

   • Minghui Zhang
   • Xiaosan Zhang
   • Qingyuan Zhang

   Original Research 15 November 2013 Pages: 349 - 357

   

8. Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment

   • Nicolas Kozakowski
   • Caroline Hartmann
   • Andrea Haitel

   Original Research 17 November 2013 Pages: 359 - 366

   

9. Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer

   • Olivera Mitrović
   • Vladan Čokić
   • Snežana Furtula

   Original Research 24 November 2013 Pages: 367 - 379

   

10. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis

    • Zhijun Li
    • Yongjun Zhang
    • Chuming Jiang

    Original Research 14 March 2014 Pages: 381 - 388

    

11. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

    • Helen N. Honma
    • Maurício W. Perroud Jr.
    • Lair Zambon

    Original Research 06 May 2014 Pages: 389 - 394

    

12. Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme

    • Joshua Mansour
    • Braxton Fields
    • Olivier Rixe

    Day-to-Day Practice 08 July 2014 Pages: 395 - 398